NCT07283081 Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias
| NCT ID | NCT07283081 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Interstitial Lung Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2026-03-16 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2026-03-16 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators hypothesize that in patients with a new diagnosis of Pulmonary Interstitial Disease (PID), adding capillaroscopy to standard care increases the proportion of patients receiving a diagnosis of PID-Connective Tissue Disease (PID-CTD) within the first three months of follow-up, thereby reducing the time to diagnosis and facilitating the implementation of appropriate treatment as quickly as possible. Therefore, To confirm this hypothesis, it is necessary to know the characteristics of capillaroscopy in patients with a new diagnosis of PID.
Eligibility Criteria
Inclusion Criteria: * Male or female over 18 years of age; * Have received a new diagnosis of PID within the last six months, confirmed by a pulmonologist; * Have undergone some specific tests within the last six months (Chest CT scan, respiratory function tests (plethysmography and CO transfer capacity measurement, immunological assessment including: screening for FAN, FR, and anti-CCP); * French-speaking patient with no comprehension difficulties; * Person affiliated with or beneficiary of a social security system; * Free, informed, and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research). Exclusion Criteria: * Have previously undergone a capillaroscopy, regardless of the reason; * Have a diagnosis or high suspicion of connective tissue disease based on initial clinical and paraclinical evaluation; * Have already started one of the following treatments for pulmonary involvement: systemic corticosteroids, immunosuppressive therapy, antifibrotic therapy; * Pregnant or breastfeeding women; * Patients covered by Articles L 1121-5 to L 1121-8 (persons deprived of their liberty by judicial or administrative decision, minors, adults subject to legal protection measures, or persons unable to give their consent).
Contact & Investigator
Marie-Elise TRUCHETET, MD, PhD
PRINCIPAL INVESTIGATOR
University Hospital, Bordeaux
Frequently Asked Questions
Who can join the NCT07283081 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Interstitial Lung Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07283081 currently recruiting?
Yes, NCT07283081 is actively recruiting participants. Contact the research team at marie-elise.truchetet@chu-bordeaux.fr for enrollment information.
Where is the NCT07283081 trial being conducted?
This trial is being conducted at Bordeaux, France.
Who is sponsoring the NCT07283081 clinical trial?
NCT07283081 is sponsored by University Hospital, Bordeaux. The principal investigator is Marie-Elise TRUCHETET, MD, PhD at University Hospital, Bordeaux. The trial plans to enroll 48 participants.